Biomay, a global leader in allergy immunotherapy, announced today that the results of a landmark phase IIb study with its 3rd generation grass pollen allergy vaccine BM32 will be reported at the EAACI Congress 2015 in Barcelona, Spain. This event is a major global scientific conference in the field of allergy and clinical immunology organized by the European Academy of Allergy and Clinical Immunology. The presentation titled "Clinical efficacy of a recombinant B cell epitope-based grass pollen allergy vaccine – a phase IIb proof of concept study" will be given by Prof. Rudolf Valenta, a globally recognized leader in allergy research, on June 7, 2015, in the Hot Topic Session of the congress.
↧